Our Co-Evolution with Cannabis

I spoke on the The Shift Network’s Plant Medicine Summit with David Crow last Thursday and  was reminded once again of the intricate connection with our plant relations. Listening to all the speakers share their stories and love of herbs filled me with deep joy. Something I realized I haven’t felt in years.

I have been cynical and fearful about the future of our planet and that heaviness has now lifted. Many of us are on the plant path and listening to wise people like Margi Flint, David Winston, and Dr. Vasant Lad, have renewed hope for the healing of so much trauma. We are on a long, evolutionary journey that spans so far into the past and future that most of us can’t even imagine.

I know cannabis is good for our personal evolution. Our endocannabinoid system tells me so. We wouldn’t have so many receptors for cannabinoids if we did not evolve alongside it. Cannabis has been cultivated in parts of Asia for at least 10,000 years and there is some evidence that we may have been using hemp as cordage for 26,000 years. With each plant that gains recognition for its medicinal properties, we move one step closer to healing ourselves and our planet. I am honored to share the medicinal and spiritual properties of cannabis, alongside all of my other herbal allies.

If you didn’t get the chance to listen to my talk on Our Co-evolution with Cannabis and would like to, sign up for my newsletter and I’ll send you a link to the talk!

With love,

jessicabaker

Jessica

when energy flows, wellness grows

Cannabis & Himalayas  Photo credit: Arne Huckelheim

Do you want to learn more about herbalism and aromatic plants?

If so, join me and other experts for a free online event: The Shift Network’s Plant Medicine Summit! 

Enjoy a vibrant you and thriving planet when you join 25+ leading ecological experts, health practitioners and inspiring educators — including David Crow, Dr. Vasant Lad, Dr. Jill Stansbury, David Winston, Sara Crow, Lakisha Jenkins, Matthew Wood, KP Khalsa, Acharya Shunya and more — as they bring to light the curative and evolutionary powers of specific medicinal plants, many of which you can grow in your own garden or neighborhood!

During this unparalleled 5-day gathering, you’ll discover:

A classic approach to reestablishing our eternal connection with Mother Nature
The cutting-edge science — and overwhelming evidence — of plant intelligence
A unique integration of herbology, Ayurveda and astrology — exploring medicinal plants related to the planets and the astrological uses of essential oils
Rare teachings of Ayurveda sages from ancient texts, bringing to light Ayurveda’s stand on environment & consciousness
“Forest Bathing” as a therapeutic practice
The use of medical cannabis oil in treating patients with cancer

Use the Earth as your healing source, March 20-24, 2017.

RSVP at no charge here: Plant Medicine Summit

I hope you join me!

With love,

jessicabaker

Jessica 

when energy flows, wellness grows

CBD is now a Schedule 1 Drug

It’s a pity that the DEA can’t see beyond their bias and continue to publicly deny the therapeutic value of cannabis. To further their renunciation of cannabis they have had to demonize a cannabinoid dubbed CBD, a THC antagonist (meaning reducing the psychoactive effect of THC), which has helped reduce the suffering of countless people with seizures, pain, cancer, and countless other conditions.

The newest research on cannabinoids is astoundingly positive if you consider neuro-protection, antagonizing tumor necrosis, and reduction of pain without life debilitating addiction a benefit to the medical community. The U.S. Health and Human Services even has a patent on the antioxidant and neuro-protective properties of cannabinoids. The mounting evidence in support of CBD has not stopped the current administration from declaring CBD (cannabidiol, a non-psychoactive cannabinoid present in cannabis) a Schedule I drug.

This decision is right on the heels of entrepreneurs and big business investing heavily in CBD oil and crystalline extract. The ability to sell CBD products online and beyond state borders without restriction seemed an easy way to get into the green rush, without the stigma or taxation of the cannabis industry. The specific scheduling of CBD (cannabis was already Schedule 1), gives no grey area as to whether or not CBD extracts are legal to sell. It appears they have established that CBD products are indeed Schedule 1. This is disappointing and is just another attempt to control the spread and acceptance of legal cannabis.

As a practitioner I am appalled that our government continues to add to the needless suffering of its citizens. As an herbalist I am concerned for what this means for all plant medicine. Making plants and their constituents illegal takes away our right to treat and prevent illness as we see fit. It is our right to have access to herbal medicine. The prohibition of one constituent makes it all too easy to prohibit another.With the recent designation of  hemp and CBD it is even more important that we dutifully educate ourselves on the benefits and application of cannabis.

wcn-jessicabaker-module7-promoI am on the faculty of the Holistic Cannabis Academy and am incredibly impressed with their program. With two tracks- one for practitioners and one for the canna-curious, they provide a high level of education and turn-key solutions for counselors and health providers with modules on business-building and marketing. Their faculty includes prestigious researchers and clinicians like Roy Upton, Ethan Russo, Jonathan Treasure, and Laura Lagano.

Empower yourself and your community by becoming a Holistic Medical Cannabis Counselor or Holistic Medical Cannabis Practitioner through the Holistic Cannabis Academy!

With love,

cropped-jessicabakerpic.png

Jessica

Photo credit: Vote Hemp

A Celebration of Cannabinoids

This blog post continues my interview with neurologist and psychopharmacology researcher, Ethan Russo. Ethan has worked with cannabis extensively since the 1990’s img-dr-ethanand continues to pioneer the research on the human endocannabinoid system. He is the former Medical Advisor to GW Pharmaceuticals and Past-President of the International Cannabinoid Research Society. What I like most about Ethan’s work is his ability to scrutinize down to an individual constituent all the while understanding the importance of the synergy of whole plant medicine.

In my final questions with Ethan,  we speak about terpenoids, the future of cannabis laboratory testing and how the FDA is responding to the labeling of CBD products.  It is my hope that these interviews help dispel the deception that has surrounded cannabis since its prohibition and help create a more informed future.

You can read the first part of the interview here Herbal Pioneers Interview with Ethan Russo

JB: The number of terpenes that are significant in lab testing is constantly changing.  Which, if any, chemical constituents are responsible for the enhancement of CBD? THC? 

ER: There have been over 200 terpenoids isolated from different cannabis chemovars, but certain ones predominate, especially myrcene in modern strains, which largely accounts for the “couchlock” that is all too common nowadays, even with cannabidiol strains that should actually be slightly stimulating, but for that.  When limonene is included in sufficient amounts, it tends to “brighten” the effect and exert a pronounced mood elevation that can be quite helpful in many chronic conditions. A rare component these days is pinene. It has a remarkable ability to counteract the short-term memory impairment engendered by THC, an effect that makes cannabis treatment problematic for patients that still need to utilize it while they work or study.

CBD is still a difficult commodity to find in many states. When present in high amounts, it will delay and blunt the peak high of THC somewhat, prolong its effect, and reduce its tendency to increase heart rate and anxiety. Beyond that, it has remarkable benefits on pain and inflammation.

JB: Since pinene is a rare component in cannabis today and has the benefit of counteracting short-term memory loss, and other herbs like pine contain pinene, is research being done on the synergist effects of other herbs with cannabis? 

ER: There may be a lot of experimentation going on out there along these lines. I have current plans for formal clinical trials to examine cannabinoid-terpenoid interactions. The protocol is all set to go—we merely need funding to initiate the experiments.

JB: I have seen the same sample of Cannabis test at different levels from different testing laboratories.  Are you familiar with the laboratory standards of establishing THC and CBD percentages? Are these percentages even remotely accurate?

ER: We need to keep in mind that virtually all the analytical labs are actually contravening federal law by doing these assays. I’m afraid the quality control in the industry is quite hit or miss, with many examples of poor work and extreme variability. There are laboratory certifications available now, and these should be encouraged. Assays of cannabinoids are difficult, and hampered often times by lack of good analytical standards from industry. The best labs develop their own. Terpenoid analysis is even more technically challenging, and few labs offer that at the present time.

JB: The FDA has sent cease and desist letters to some CBD product manufacturers stating that there is some evidence of medicinal use and so cannot be sold as a dietary supplement.  Do you believe research has proven that Cannabis has several medicinal properties? 

ER: It is certain that cannabis has many medicinal properties. Just as a simple example, Sativex® (USAN: nabiximols), a cannabis-based oromucosal spray is approved as a prescription pharmaceutical in 27 countries for spasticity (muscle tightness) in multiple sclerosis. In Canada, it is also approved for pain in MS and in cancer unresponsive to optimized opioid treatment. Another cannabis-based medicine, Epidiolex®, an almost pure cannabidiol extract should be soon approved by the FDA in the USA for treatment of intractable epilepsy in children. However, approval of such a pharmaceutical form of cannabis will not influence the scheduling of other cannabis products. The FDA first went after CBD producers that had no cannabidiol in their products. Now they are issuing cease and desist letters to other companies that are exaggerating the CBD content, or making unsubstantiated medical claims. Rather, structure-function statements should be the maximum claim, as is currently the situation with other herbal products in the USA.

While we’re at it, for better or worse, cannabidiol is still a Schedule I forbidden drug in this country. Claims to the contrary, such as “Our CBD is derived from hemp and is legal in all 50 states,” are a function of tortured legal logic and wishful thinking.

JB: Ethan, thank you for participating in this interview and for your diligence in spreading the truth about cannabis.

To see Ethan Russo speak in person, attend the Medicinal Cannabis Conference in Arcata, California April 23-24, 2016 http://www.medicalmarijuanaconference.net/?page_id=246

For more information on Ethan’s work and our endocannabinoid system, check out

researchgate.net/profile/ethan_russo/contributions

phytecs.com

Happy 420 everyone!  We have witnessed the end of cannabis prohibition and an evolutionary leap of consciousness.

When energy flows, wellness grows

Abundant Blessings,

cropped-jessicabakerpic.png

Jessica

Herbal Pioneers Interview with Ethan Russo

img-dr-ethanI am honored to begin my Herbal Pioneers Interview Series with an interview with neurologist and psychopharmacology researcher, Ethan Russo. Ethan has worked with cannabis extensively since the 1990’s and continues to pioneer the research on the human endocannabinoid system. He is the former Medical Advisor to GW Pharmaceuticals and Past-President of the International Cannabinoid Research Society. What I like most about Ethan’s work is his ability to scrutinize down to an individual constituent all the while understanding the importance of the synergy of whole plant medicine.

This became a two-part series as I like to keep my blog posts short and I encourage readers to take the time to follow the links Dr. Russo provides for more in depth answers to the questions.  In the first interview Ethan describes how he began researching cannabinoids, debunks the terms “sativa” and “indica” and explains how those descriptions have nothing to do with the effects attributed to them. (Thank You-this has been a pet peeve of mine for a long time!)  In next week’s blog we discuss terpenoids, the future of cannabis laboratory testing and how the FDA is responding to the labeling of CBD products.

JB:  Ethan, thank you for participating in this interview and for your diligence in spreading the truth about cannabis.

Aa young scientist, what inspired you to research the constituents present in the Cannabis plant?

ER: After several years in practice, I came to believe that I was giving increasingly toxic pharmaceuticals to my patients with less and less progress. Some of my patients were employing adjunctive cannabis to treat their illnesses even back in the 1980s, especially multiple sclerosis. This caused me to look back to my teenage interest in medicinal herbs. I then embarked on a mission to find herbal agents to treat migraine more effectively. The greatest abundance of herbal agents is found in the Amazon, so I took Spanish classes once a week for a year and a half before two trips to Peru. The second took place in 1995, when I spend the bulk of a three-month sabbatical working with the Machiguenga tribe in Parque Nacional del Manù. They had a great abundance of psychoactive agents and migraine treatments. Shortly after my return, I became embroiled in the clinical cannabis controversy. Over the next several years, I experienced continual federal roadblocks to that research and began writing, editing and lecturing on the subject, and eventually, in 2003, it became the primary focus of my work.

JB: Have you published (or will publish) anything on your work with the Machiguenga tribe? 

ER: Yes. I wrote an article on the Machiguenga tribe’s diet and its pertinence to Nourishing Traditions by Sally Fallon. It is accessible here: http://www.westonaprice.org/health-topics/machiguenga-peruvian-hunter-gatherers/

JB: What is your opinion on the debate on whether there are two different species Cannabis sativa or Cannabis indica (more if you include ruderalis or afghanica) or if all cannabis plants are Cannabis sativa

ER: I have personally been on every side of this issue. The botanical taxonomists will never agree. To be sure, the way that the terms “sativa” and “indica” are applied in common parlance is absolute nonsense. What consumers need to know is the actual chemical composition of the cannabis, both cannabinoids and terpenoids, in an accurate fashion by a reliable laboratory to have a better idea of its likely effects. I recently was interviewed on this subject at greater length, which is available here: http://online.liebertpub.com/doi/pdfplus/10.1089/can.2015.29003.ebr

Read next weeks 420 blog post with the second part of the interview and celebratory post!

To see Ethan Russo speak in person, attend the Medicinal Cannabis Conference in Arcata, California April 23-24, 2016  Medicinal Cannabis Conference Website

For more information on Ethan’s work and our endocannabinoid system, check out researchgate.net/profile/ethan_russo/contributions and phytecs.com

When energy flows, wellness grows

Abundant Blessings,

cropped-jessicabakerpic.png

Jessica